GlassScriptPhysician profile
Nitin Govani
NPI 1619079050
$1,979.69
in general payments reported to CMS, 2019-2025
25 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $199 · 2022: $165 · 2023: $226 · 2024: $323 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $297.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $186.57 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.65 | 2022-2023 | |
| Lundbeck LLC | $159.50 | 2023-2025 | Rexulti |
| Pfizer INC. | $142.98 | 2019-2025 | |
| Olympus America INC. | $138.31 | 2025 | Itind System |
| Lilly USA, LLC | $108.94 | 2019-2025 | Mounjaro, Zepbound |
| Sunovion Pharmaceuticals INC. | $93.58 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $75.25 | 2024-2025 | Rexulti |
| Abbott Laboratories | $62.60 | 2023-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $51.92 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $51.65 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $46.68 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $44.99 | 2019-2020 | |
| Exact Sciences Corporation | $42.85 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $39.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.71 | 2019 | |
| Astellas Pharma US INC | $37.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $33.88 | 2023-2025 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $33.81 | 2024-2025 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $31.89 | 2025 | Hetlioz, Fanapt |
| Coloplast Corp | $30.18 | 2019 | |
| Scpharmaceuticals INC. | $22.17 | 2025 | |
| Sumitomo Pharma America, INC. | $21.75 | 2024 | Gemtesa |
| Allergan, INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Govani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.